← Damian Garda

What podcasts say about Damian Garda

Every statement, with the speaker, the exact quote and the moment it was said.

What Damian Garda has said on podcasts

8 statements · 4 positive · 1 negative · 2 mixed · 1 neutral

  1. on Chinese biotech industryPositiveNov 20, 2026· The Readout Loud

    Chinese biotech consists of competing firms with diverse strategies and histories.

    “the Chinese biotech industry is described as a monolith. But that, of course, is not... how it is. It couldn't be further from the truth. It is rather a bunch of competing firms with differing strategies, differing histories, differing approaches to making medicines for human beings.”

    Listen at 2:18

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  2. on Chinese biotech industryPositiveNov 20, 2026· The Readout Loud

    China’s biotech and scientific rise is highly important to global health’s future.

    “The remarkable ascendance of not just the Chinese biotech industry, but the Chinese scientific apparatus, whether it's in academia or industry, is massively important to everything we cover and to the future of global health.”

    Listen at 2:57

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  3. on B1 MedicinesPositiveNov 20, 2026· The Readout Loud

    B1 Medicines ranks first in the China biotech powerhouse index.

    “It is B1 Medicines, formerly Baijin, I believe is how it was pronounced, which is an interesting firm in that they were designed to straddle East and West.”

    Listen at 4:28

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  4. on Hangry PharmaceuticalsPositiveNov 20, 2026· The Readout Loud

    B1 Medicines and Hungry Pharmaceuticals each have approximately $50 billion market capitalizations.

    “each has a market cap of about $50 billion.”

    Listen at 5:12

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  5. The outcomes of B1 Medicines’ and Hungry Pharmaceuticals’ strategies remain uncertain.

    “we'll see which of those strategies plays out.”

    Listen at 5:28

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  6. on Treasury proposed rule on U.S.-China biotech investmentNeutralNov 20, 2026· The Readout Loud

    The proposed Treasury rule appears to exempt conventional drug-licensing deals with Chinese companies.

    “the proposed rule as written appears to carve out the kind of deals we seem to see once a week where the likes of Pfizer or Bristol-Myers Squibb or Merck licenses a medicine from a Chinese company.”

    Listen at 7:17

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  7. on Treasury proposed rule on U.S.-China biotech investmentNegativeNov 20, 2026· The Readout Loud

    The proposed rule would harm America’s venture-capital community by restricting complex China biotech deals.

    “what would be affected is something that would be much more deleterious to america's venture capital community which is more complicated deals”

    Listen at 7:31

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers
  8. on Treasury proposed rule on U.S.-China biotech investmentMixedNov 20, 2026· The Readout Loud

    The proposed Treasury rule may change substantially or never be implemented.

    “American firms taking equity in Chinese firms. This will all get ironed out. And as with any proposed rule change, if implemented, it could be quite different. It could also never be implemented.”

    Listen at 7:56

    Open the episode · 422: FDA's search for a new leader, and China's largest drugmakers

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.